Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CloB2M Conditioning Regimen in Allo-HSCT for Adult AML in CR1
NCT07644481Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2029
01
Overview
Open-label, single-arm trial of clofarabine, busulfan and melphalan in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall Survival at 2 years. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
clofarabinebusulfanmelphalan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07644481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644481.